52
Participants
Start Date
December 15, 2016
Primary Completion Date
November 22, 2021
Study Completion Date
May 1, 2025
Durvalumab
Tremelimumab
BCCA - Cancer Centre for the Southern Interior, Kelowna
BCCA - Vancouver Cancer Centre, Vancouver
CancerCare Manitoba, Winnipeg
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
Kingston Health Sciences Centre, Kingston
London Regional Cancer Program, London
Ottawa Hospital Research Institute, Ottawa
Odette Cancer Centre, Toronto
University Health Network, Toronto
Allan Blair Cancer Centre, Regina
Saskatoon Cancer Centre, Saskatoon
Collaborators (1)
AstraZeneca
INDUSTRY
Canadian Cancer Trials Group
NETWORK